Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Simian virus-40 infection inhibits DNA damage-induced enhancement of CD95 expression and function

Oncogene volume 21, pages 190–197 (2002)Cite this article

Abstract

Many viruses are known to disarm or suppress the cell death machinery of infected cells. Apoptotic cell death can be activated by aggregation of the CD95 cell surface death receptor in sensitive cells, and in most insensitive cells treated with sensitizing agents such as interferon-gamma or inhibitors of protein synthesis. We show that, subsequent to sequestration and inactivation of the p53 tumour suppressor protein, SV40 abrogates p53-dependent, DNA damage-inducible up-regulation of CD95 surface expression. Loss of surface up-regulation of CD95 after sub-lethal mitomycin C treatment resulted in an impaired enhancement of both caspase-8 cleavage and apoptotic cell death following CD95 aggregation. We conclude that infection of human cells with SV40 virus strongly inhibits DNA damage-induced enhancement of CD95-mediated apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, Nieruchalski M, May E . 2000 Oncogene 19: 649–660

  • Broome HE, Dargan CM, Brunner T, Green DR . 1998 Cell Death Differ. 5: 200–205

  • Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B . 1998 Science 282: 1497–1501

  • Butel JS, Lednicky JA . 1999 J. Natl. Cancer Inst. 91: 199–134

  • Carbone M, Fisher S, Powers A, Pass HI, Rizzo P . 1999 J. Cell Physiol. 180: 167–172

  • Caulin C, Salvesen GS, Oshima RG . 1997 J. Cell Biol. 138: 1379–1394

  • Conzen SD, Snay CA, Cole CN . 1997 J. Virol. 71: 4536–4543

  • Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG . 1997 Br. J. Haematol. 96: 584–593

  • Fanning E, Knippers R . 1992 Annu. Rev. Biochem. 61: 55–85

  • Fulda S, Los M, Friesen C, Debatin KM . 1998 Int. J. Cancer 76: 105–114

  • Gonin S, Diaz-Latoud C, Richard MJ, Ursini MV, Imbo A, Manero F, Arrigo AP . 1999 Oncogene 18: 8011–8023

  • Gutierrez del Arroyo A, Gil-Lamagniere C, Lazaro I, de Marco MC, Layunta I, Silva A . 2000 Oncogene 19: 3647–3655

  • Harlow E, Crawford LV, Pim DC, Williamson NM . 1981 J. Virol. 39: 861–869

  • Harty JT, Tvinnereim AR, White DW . 2000 Annu. Rev. Immunol. 18: 275–308

  • Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H . 1999 J. Immunol. 163: 583–589

  • Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J . 2000 Nat. Immunol. 1: 489–495

  • Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM . 1995 Oncogene 10: 2297–2305

  • Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace Jr AJ . 1992 Cell 71: 587–597

  • Kimura K, Gelmann EP . 2000 J. Biol. Chem. 275: 8610–8617

  • Krammer PH . 1999 Adv. Immunol. 71: 163–210

  • Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB . 1992 Proc. Natl. Acad. Sci. USA. 89: 7491–7495

  • Lane DP, Crawford LV . 1979 Nature 278: 261–263

  • Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Trout RH . 2000 J. Immunol. 164: 231–239

  • Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P . 1993 Lab. Invest. 69: 415–429

  • Levresse V, Moritz S, Renier A, Kheuang L, Galateau-Salle F, Mege JP, Piedbois P, Salmons B, Guenzburg W, Jaurand MC . 1998 Oncogene 16: 1041–1053

  • Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H . 1997 Genes Dev. 11: 663–677

  • Maecker HL, Koumenis C, Giaccia AJ . 2000 Cancer Res. 60: 4638–4644

  • Matsumura H, Shimizu Y, Ohsawa Y, Kawahara A, Uchiyama Y, Nagata S . 2000 J. Cell Biol. 151: 1247–1256

  • Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, Harris CC . 1992 Cancer Res. 52: 2610–2615

  • Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT . 1997 J. Natl. Cancer Inst. 89: 783–789

  • Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM . 1992 J. Cell Sci. 101: 183–189

  • Mor O, Read M, Fried M . 1997 Oncogene 15: 3113–3119

  • Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR . 1997 J. Clin. Invest. 99: 403–413

  • Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH . 1998 J. Exp. Med. 188: 2033–2045

  • Nguyen PL, Harris NL, Ritz J, Robertson MJ . 1996 Am. J. Pathol. 148: 847–853

  • O'Connor L, Harris AW, Strasser A . 2000 Cancer Res. 60: 1217–1220

  • Okayasu R, Takahashi S, Yamada S, Hei TK, Ullrich RL . 1999 Cancer Res. 59: 298–300

  • Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S . 1994 Cancer Res. 54: 1580–1586

  • Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R . 1995 Mol. Cell. Biol. 15: 3032–3040

  • Quartin RS, Cole CN, Pipas JM, Levine AJ . 1994 J. Virol. 68: 1334–1341

  • Rodier F, Bertrand R, Bossolasco M, Mes-Masson AM . 2000 Oncogene 19: 6261–6270

  • Rosen D, Li JH, Keidar S, Markon I, Orda R, Berke G . 2000 J. Immunol. 164: 3229–3235

  • Rouquet N, Allemand I, Molina T, Bennoun M, Briand P, Joulin V . 1995 Oncogene 11: 1061–1067

  • Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH . 1998 J. Immunol. 161: 3957–3965

  • Sayers TJ, Brooks AD, Seki N, Smyth MJ, Yagita H, Blazar BR, Malyguine AM . 2000 J. Leukoc. Biol. 68: 81–86

  • Screpanti V, Wallin RP, Ljunggren HG, Grandien A . 2001 J. Immunol. 167: 2068–2073

  • Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J . 1997 Int. J. Cancer 73: 757–762

  • Sheard MA, Krammer PH, Zaloudik J . 1999 Br. J. Cancer 80: 1689–1696

  • Simanis V, Lane DP . 1985 Virology 144: 88–100

  • Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, Mumby M . 1993 Cell 75: 887–897

  • Stephen CW, Helminen P, Lane DP . 1995 J. Mol. Biol. 248: 58–78

  • Topham DJ, Tripp RA, Doherty PC . 1997 J. Immunol. 159: 5197–5200

  • Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL . 2000 Annu. Rev. Immunol. 18: 861–926

  • Tsai SC, Pasumarthi KB, Pajak L, Franklin M, Patton B, Wang H, Henzel WJ, Stults JT, Field LJ . 2000 J. Biol. Chem. 275: 3239–3246

  • Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W, Vandenabeele P . 1998 J. Exp. Med. 188: 919–930

  • Vojtesek B, Bartek J, Midgley CA, Lane DP . 1992 J. Immunol. Methods 151: 237–244

  • Vousden KH . 2000 Cell 103: 691–694

  • Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH . 2001 J. Clin. Invest. 108: 51–62

Download references

Acknowledgements

The authors thank M Svitakova and S Babcenova for technical expertise. MS was supported by a grant from the Grant Agency of the Czech Republic 301/00/0563 and by the Internal Grant Agency of the Ministry of Health (IGA) NC6402-3/2000; BV was supported by IGA 6404-3.

Author information

Authors and Affiliations

  1. Laboratory of Apoptosis Research, Masaryk Memorial Cancer Institute, Zluty Kopec 7, Brno, 656 53, The Czech Republic

    Michael A Sheard

  2. Department of Experimental Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, Brno, 656 53, The Czech Republic

    Borivoj Vojtesek

Authors
  1. Michael A Sheard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Borivoj Vojtesek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A Sheard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sheard, M., Vojtesek, B. Simian virus-40 infection inhibits DNA damage-induced enhancement of CD95 expression and function. Oncogene 21, 190–197 (2002). https://doi.org/10.1038/sj.onc.1205043

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205043

Keywords

Search

Advanced search

Quick links